All In MedTech

FDA Clearance Tracker · P090013-S107

REVO MRI IPG

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 27, 2013 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 27, 2013

Approved

Time to decision

81 days

Received Jul 8, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P090013-S107
Device name
REVO MRI IPG
Applicant location
Mounds View, MN
Received
Jul 8, 2013
Decided
Sep 27, 2013
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P090013

Device type

Device class
Class III

Every decision under product code LWP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE MYCARELINK PATIENT MONITOR MODELS 24950 (SOFTWARE VERSION R50), 24951 (SOFTWARE VERSION R50.A.1), AND 24955 (SOFTWARE VERSION V29) TO BE USED WITH THE DEVICES.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.